Home » USA Broker Ratings » Mylan N.V. – Consensus Indicates Potential 38.9% Upside

Mylan N.V. – Consensus Indicates Potential 38.9% Upside

Mylan N.V. found using ticker (MYL) have now 15 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 29 and 17 with a mean TP of 22.07. With the stocks previous close at 15.89 this now indicates there is a potential upside of 38.9%. There is a 50 day moving average of 16.56 and the 200 day moving average is 17.84. The market capitalisation for the company is $8,266m. Find out more information at: http://www.mylan.com

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women’s health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals; Theravance Biopharma; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics The company was founded in 1961 and is based in Hatfield, the United Kingdom.

Join us on our new LinkedIn page

Follow us on LinkedIn